The market CTIX trades on is relevant to the science. CTIX raises funds to keep the company afloat. There's been small biotech companies who have had science, but lost everything. Prime example Polymedix, which is how CTIX got B. I wouldn't be so confident "in saying" it doesn't matter what market they trade on? CTIX has funding for the current phase trials, but will need way more cash next year and so on... A PPS being manipulated is currently CTIX's credit line.